medigraphic.com
ISSN 1561-3054 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cubana Med Trop 2021; 73 (3)

Preliminary evaluation of the antiviral activity of Ageratina havanensis against dengue-2 virus using enzyme immunoassays

Pupo AM, Medero DD, Vázquez RS, Morier DLF, Álvarez VM, del Barrio AG

Language: Spanish
References: 29
Page: 1-19
PDF size: 526.20 Kb.


ABSTRACT

Introduction: A preliminary evaluation is presented of the antiviral activity of Ageratina havanensis extracts (stem ethanolic, AH-T-EtOH; leaf butanolic, AH-H-ButOH; and leaf ethyl acetate, AH-H-AcEtO) using two enzyme immunoassays, cellular ELISA (C-ELISA) and immunoperoxidase technique.
Objective: Evaluate the antiviral activity of Ageratine havanensis extracts using two enzyme immunoassays.
Methods: C-ELISA and immunoperoxidase technique were standardized for use in the preliminary evaluation of the antiviral activity of three Ageratina havanensis extracts at different concentrations and addition times through detection of the expression of the E protein of dengue virus.
Results: C-ELISA achieved the following optimal parameters: Vero cell line, viral antigen in cell culture, protein E expression time 96 h, methanol-acetone fixation compound and 1% skimmed milk blocker. The smallest expression of protein E (greatest inhibition over viral replication) was achieved at addition of extract AH-T-EtOH at its highest concentration and 1 h before inoculating dengue-2 virus strain A15 (VDEN-2 A15). Extract AH-H-ButOH at concentrations of 125 µg/ml and 250 µg/ml presented a slight limitation in the expression of E 1 h after viral inoculation. Extract AH-H-AcEtO at the concentrations used did not show any difference when added before and after inoculation. The immunoperoxidase assay exhibited similar results for the extracts.
Conclusions: The greatest inhibition of viral replication was obtained with extract AH-H-ButOH at its highest concentration and at both addition times. The enzyme immunoassays applied are useful tools to evaluate Ageratine havanensis extracts with potential antiviral activity.


REFERENCES

  1. Whitehorn JA, Yacoub S. Global warming and arboviral infections. Clinical Medicine. 2019 [acceso: 04/02/2021];19(2):149-52. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30872300/

  2. Yacoub S, Mongkolsapaya J, Screaton G. Recent advances in understanding dengue. 2016. Doi: https://doi.org/10.12688/f1000research.6233.1

  3. Hidari K, Abe T and Suzuki T. Crabohydrate-Related Inhibitors of Dengue Virus Entry. Viruses. 2013 [acceso: 04/02/2021];5:605-618. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/23389466/

  4. Mazumder R, Hu ZZ, Vinakaya CR, Sagripanti JL, Frost SD. Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes. 2007 [acceso: 04/02/2021];35:175-86. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/17508277/

  5. Ng ML, Corner LC. Detection of some dengue-2 virus antigens in infected cells using immuno-microscopy. Arch Virol. 1989 [acceso: 04/02/2021];104:197-208. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/2650656/

  6. Vázquez S, Pupo M, Pelegrino JL, Morier L, Castillo A, Otero A, et al. Ensayo inmunoenzimático para la detección de anticuerpos monoclonales contra las proteínas E y NS1 del virus dengue. Rev Cubana Med Trop. 1995 [acceso: 04/02/2021];47(2):1-5. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/9805082/

  7. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, et al. Ten years of dengue drug discovery: Progress and prospects. Antivir Res. 2013 [acceso: 04/02/2021];100 .500-19. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/24076358/

  8. Texeira R, Pereira W, Costa de Silveira A, Da Silva A, Silva A, Lopes M, et al. Natural Products as Source of Potencial Dengue Antivirals. Molecules. 2014 [acceso: 04/02/2021];19:8151-76. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/24941340/

  9. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard C, Cooke S, et al. Structure and functionality in flavivirus NS-proteins: Perspectives for drug design. The VIZIER project: deciphering the world of RNA viruses. Antiviral Research. 2010 [acceso: 04/02/2021];87(2):125-48. Doi: https://doi.org/10.1016/j.antiviral.2009.11.009

  10. Qing M, Liu W, Yuan Z, Gu F, Shi PY. A high-throughput assay using dengue-1 virus-like particles for drug discovery. Antiviral Res. 2010 [acceso: 04/02/2021];86:163-71. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20153777/

  11. Koishi AC, Zanello PR, Bianco EM, Bordignon J, Nunes Duarte dos Santos C. Screening of Dengue Virus Antiviral Activity of Marine Seaweeds by an In Situ Enzyme-Linked Immunosorbent Assay. PLoS ONE. 2012 [acceso: 04/02/2021];7(12):1-11. Doi: https://doi.org/10.1371/journal.pone.0051089

  12. Silva A, Morais MS, Marques M. Antiviral activities of extracts and phenolic components of two Spondias species against dengue virus. The Journal of Venomous Animals and Toxins Including Tropical Diseases. 2011 [acceso: 04/02/2021];17:406-13. Disponible en: Disponible en: https://www.scielo.br/pdf/jvatitd/v17n4/07.pdf

  13. Marlina S, Shu MH, Abubakar S, Zandi K. Development of a Real- Time Cell Analysing (RTCA) method as a fast and accurate screen for the selection of chikungunya virus replication inhibitors. Parasites & Vectors. 2015;8:579. Doi: https://doi.org/10.1186/s13071-015-1104-

  14. Kourí G, Mas P, Guzmán MG, Soler M, Goyenechea A, Morier L. Dengue hemorrhagic fever in Cuba, 1981: rapid diagnosis of the etiologic agent. Bull Pan Am Health Organ. 1983 [acceso: 08/02/2021];17:126-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/6626806

  15. Morens DM, Halstead SB, Repik PM, Putvatana RP, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semi-micro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol. 1985 [acceso: 04/02/2021];22:250-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC268369/ .

  16. del Barrio Alonso GC, Jardines Figueredo Y, Spengler Salabarría I, García Pérez TH, Roque Quintero A, Alvarez Vera M. Evaluación preliminar de la actividad de Ageratina havanensis contra virus dengue 2. Rev Cubana Med Trop. 2021 [acceso: 04/02/2021];73(1):e573. Disponible en: Disponible en: http://revmedtropical.sld.cu/index.php/medtropical

  17. Hermida C, Pupo M, Guzmán MG, González M, Marcet R. Use of a dengue anti-complex monoclonal antibody in viral purification. Rev Cubana Med Trop 1992;44:171-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9768210/

  18. Vázquez S, Valdés O, Pupo M, Delgado I, Álvarez M, Pelegrino JL. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods. 2003 [acceso: 14/02/2021];110:179-84. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/12798246/

  19. Clarke DH, Casals J. Techiques for hemagglutination and hemagglutination inhibition with arthropod-borne viruses. American Journal of Tropical Medicine and Hygiene. 1958 [acceso: 04/02/2021];7:561-573. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/13571577/

  20. Vázquez S, Pupo M, Pelegrino JL, Morier L, Castillo A, Otero A, et al. Ensayo inmunoenzimático para la detección de anticuerpos monoclonales contra las proteínas E y NS1 del virus dengue. Rev Cubana Med Trop. 1995 [acceso: 04/02/2021];47(2):1-5. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07601995000200009

  21. Vázquez Y, Pupo-Antúnez M, Vázquez S, Capó V, Torres G, Caballero Y, et al. Monoclonal antibody to dengue capsid protein. Its application in dengue studies. mAbs. 2009 [acceso: 04/02/2021];(1:2):157-162. Disponible en: Disponible en: http://www.landesbioscience.com/journals/mabs/article/7908

  22. Zhuab L. The evaluation of an immunoperoxidase assay applicable in antiviral drug screening. Biologicals. 2019;57:61-6. Doi: https://doi.org/10.1016/j.biologicals.2018.10.006

  23. Talarico LB, Pujol CA, Zibetti RG, Faria PC, Noseda MD, Duarte ME, et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005 [acceso: 14/02/2021];66:103-10. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/15911027/

  24. Myc A, Anderson MJ, Baker JR. Optimization of in situ cellular ELISA performed on influenza A virus-infected monolayers for screening of antiviral agents. Journal of Virological Methods. 1999 [acceso: 04/02/2021];77:165-77. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/10092140/

  25. Samoszuk M, Sholly S, Epstein AL. Screening for anti-idiotypic monoclonal antibodies on paraformaldehyde-fixed lymphoma cells. Hybridoma. 1987 [acceso: 04/02/2021];6:605-10. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/3325402/

  26. Kiernan JA. Fixation. En: Alan J. eds. Histological and Histochemical Methods: Theory and Practice. Pergamon Press,1990. p. 25-7. [acceso: 04/02/2021], Disponible en: Disponible en: https://www.amazon.es/Histological-Histochemical-Methods-Theory-Practice/dp/0080362230

  27. Del Barrio G, Spengler I, García T, Roque A, Alvarez A. Antiviral activity of Ageratina havanensis and major chemical compounds from the most active fraction. Brazilian Journal of Pharmacognosy. 2011 [acceso: 14/02/2021];21(5):915-20. Disponible en: Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000500020

  28. Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, AbuBakar S. Novel antiviral activity of baicalein against dengue virus. BMC Complementary and Alternative Medicine. 2012;12:214. Doi: https://doi.org/10.1186/1472-6882-12-214.

  29. Limonta D, Falcón V, Torres G, Capo V, Menendez I. Dengue virus identification by transmission electron microscopy and molecular methods in fatal dengue hemorrhagic fever. Infection. 2012;40(1):1-8. Doi: https://doi.org/10.1007/s15010-012-0260-7




2020     |     www.medigraphic.com